Hematologi og onkologi
Kostnadsbesparelser
Systematisk og multimodal behandling
Impact of a patient blood management monitoring and feedback programme on allogeneic blood transfusions and related costs. (åpner nytt vindu)
Kilde: Anaesthesia 2019;74(12):1534-41.
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (åpner nytt vindu)
Kilde: Blood Adv. 2022;6(3):785-92.
Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (åpner nytt vindu)
Kilde: Transfusion 2017;57(9):2189-96.
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (åpner nytt vindu)
Kilde: Transfusion 2015;55(12):2807-15.
Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (åpner nytt vindu)
Kilde: Transfusion 2010;50(2):487-92.
Behandling av anemi
Should intravenous iron be the standard of care in oncology? (åpner nytt vindu)
Kilde: J Clin Oncol 2008;26(10):1579-81.
Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (åpner nytt vindu)
Kilde: Blood Transfus 2020;18(2):106-16.
The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model. (åpner nytt vindu)
Kilde: Acta Oncol 2008;47(6):1009-17.
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (åpner nytt vindu)
Kilde: Support Care Cancer 2013;21(2):485-93.
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (åpner nytt vindu)
Kilde: Cancer 2013;119(1):107-14.
Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (åpner nytt vindu)
Kilde: Cost Eff Resour Alloc 2013;11(1):16.
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (åpner nytt vindu)
Kilde: Support Care Cancer 2012;20(1):159-65.
Hemostatika
Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (åpner nytt vindu)
Kilde: Clin Ther 2010;32(14):2478-93.
Recombinant activated factor VII use in critically ill infants with active hemorrhage. (åpner nytt vindu)
Kilde: J Pediatr Surg 2008;43(12):2235-8.
Perioperativ/intraoperativ blodsparing og blodgjenvinning
Restrictive blood transfusion practices are associated with improved patient outcomes. (åpner nytt vindu)
Kilde: Transfusion 2014;54(10 Pt 2):2753-9.
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (åpner nytt vindu)
Kilde: Hematology 2018;23(7):417-22.
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (åpner nytt vindu)
Kilde: Am J Hematol 2010;85(10):795-7.